Third, the expression of other immune molecules should be detected together with the LAG-3 and PD-L1 to better understand the mechanism of TACE therapy affecting tumor immunity, so as to provide theoretical basis for the combination of TACE and immunotherapy in HCC patients. This evidence concerns the gene LAG3 and hepatocellular carcinoma.